ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

AstraZeneca-Oxford vaccine safe and effective, new trial shows

As EU resumes use of jab, company hopes to gain US emergency approval

A large trial in Chile, Peru and the U.S. of the AstraZeneca-Oxford University vaccine has shown that it is 100% effective against severe or critical disease and hospitalization.   © Reuters

FRANKFURT/LONDON (Reuters) -- AstraZeneca's COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States, the company said on Monday, paving the way for it to apply for U.S. approval.

The vaccine was also 100% effective against severe or critical disease and hospitalization, and was safe, the partners said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more